Suppr超能文献

人多形性胶质母细胞瘤中血管成分的增殖潜能

Proliferative potential of vascular components in human glioblastoma multiforme.

作者信息

Nagashima T, Hoshino T, Cho K G

出版信息

Acta Neuropathol. 1987;73(3):301-5. doi: 10.1007/BF00686626.

Abstract

Sixteen patients with glioblastoma multiforme received a 1-h intravenous infusion of 5-bromo-deoxyuridine (BrdU), 150-200 mg/m2 at the start of surgery, to label S-phase cells in tumor tissue. Labeled cells of vascular components and of tumor parenchyma were detected in excised tumor specimens by indirect immunoperoxidase staining using anti-BrdU monoclonal antibodies followed by periodic acid-Schiff staining. The BrdU labeling index (LI, defined as the percentage of labeled cells in relation to the total number of cells scored) was calculated separately for vascular components and tumor parenchyma in each specimen. The BrdU LI of vascular components of glioblastoma multiforme was remarkably higher than that of normal brain (1.1%-8.7% vs. less than 0.05%). The mean BrdU LIs of vascular components and tumor cells in eight primary glioblastomas were 4.5 +/- 0.8% (mean +/- SE) and 9.9 +/- 1.1%, respectively, while the corresponding BrdU LIs in eight recurrent tumors were 2.7 +/- 0.5% and 9.3 +/- 0.7%. The differences in the BrdU LIs of primary and recurrent tumors were not statistically significant, but the BrdU LI of vascular components was consistently much lower than that of tumor cells. BrdU labeling of vascular components was inconsistent and occurred mostly in glomerular-shaped vessels, but only about 20% of them contained labeled cells. These results suggest that unusual vascular proliferation, such as the formation of glomerular-shaped vessels and endothelial or adventitial proliferation, in glioblastoma multiforme may have been programmed to slow down or even to cease at a certain stage, and is not likely to be the result of neoplastic transformation.

摘要

16例多形性胶质母细胞瘤患者在手术开始时接受1小时静脉输注5-溴脱氧尿苷(BrdU),剂量为150-200mg/m²,以标记肿瘤组织中的S期细胞。使用抗BrdU单克隆抗体通过间接免疫过氧化物酶染色,随后进行过碘酸-希夫染色,在切除的肿瘤标本中检测血管成分和肿瘤实质的标记细胞。分别计算每个标本中血管成分和肿瘤实质的BrdU标记指数(LI,定义为标记细胞数占计分细胞总数的百分比)。多形性胶质母细胞瘤血管成分的BrdU LI显著高于正常脑(1.1%-8.7%对小于0.05%)。8例原发性胶质母细胞瘤中血管成分和肿瘤细胞的平均BrdU LI分别为4.5±0.8%(平均值±标准误)和9.9±1.1%,而8例复发性肿瘤中相应的BrdU LI分别为2.7±0.5%和9.3±0.7%。原发性和复发性肿瘤的BrdU LI差异无统计学意义,但血管成分的BrdU LI始终远低于肿瘤细胞。血管成分的BrdU标记不一致,主要发生在肾小球样血管中,但其中只有约20%含有标记细胞。这些结果表明,多形性胶质母细胞瘤中异常的血管增殖,如肾小球样血管的形成以及内皮或外膜增殖,可能在某个阶段已被编程减缓甚至停止,不太可能是肿瘤转化的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验